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Abstract 
Rationale: Mutations of SLC26A4 that abrogate pendrin, expressed in endolymphatic sac, cochlea and 
vestibule, are known to cause autosomal recessive sensorineural hearing loss with enlargement of the 
membranous labyrinth. This is the first study to demonstrate the feasibility of gene therapy for 
pendrin-related hearing loss.  
Methods: We used a recombinant viral vector to transfect Slc26a4 cDNA into embryonic day 12.5 
otocysts of pendrin-deficient knock-out (Slc26a4∆/∆) and pendrin-deficient knock-in 
(Slc26a4tm1Dontuh/tm1Dontuh) mice.  
Results: Local gene-delivery resulted in spatially and temporally limited pendrin expression, prevented 
enlargement, failed to restore vestibular function, but succeeded in the restoration of hearing. Restored 
hearing phenotypes included normal hearing as well as sudden, fluctuating, and progressive hearing loss.  
Conclusion: Our study illustrates the feasibility of gene therapy for pendrin-related hearing loss, 
suggests differences in the requirement of pendrin between the cochlea and the vestibular labyrinth, and 
documents that insufficient pendrin expression during late embryonal and early postnatal development of 
the inner ear can cause sudden, fluctuating and progressive hearing loss without obligatory enlargement 
of the membranous labyrinth. 
Key words: Solute carrier family 26 member 4; Enlarged vestibular aqueduct; Recombinant adeno-associated 
virus; Gene therapy; In-utero; Pendred syndrome 
Introduction 
Mutations in the SLC26A4 gene, which encodes 
the anion exchanger pendrin, are worldwide the 
second most prevalent cause of hereditary hearing 
loss; the most prevalent causes are mutations of GJB2 
[1]. In some large populations, including those of East 









patients with hereditary hearing loss [2, 3]. Mutations 
of SLC26A4 cause hearing loss associated with 
enlargement of the vestibular aqueduct (EVA), which 
can be non-syndromic (DFNB4, OMIM #600791) or 
syndromic with thyroid goiter (Pendred syndrome, 
OMIM #605646) [4, 5]. Hearing loss can be profound 
at birth or fluctuating and progressive during 
childhood [6-8]. Vestibular dysfunction is common 
but often well compensated [9]. 
The inner ear is comprised of the cochlea, 
vestibule, and endolymphatic sac (Figure 1A). The 
cochlea and vestibule detect mechanical stimulations 
such as sound waves and linear or angular 
accelerations and the endolymphatic sac regulates 
endolymph volume [10]. Endolymph, the luminal 
fluid of the inner ear, has unique ionic compositions 
such as high [K+] and low [Na+] in the cochlea and 
vestibule and high [Na+] and low [K+] in the 
endolymphatic sac [11]. The unique ionic milieu of 
endolymph, which is required for normal hearing and 
vestibular function, is regulated by various ion 
channels, transporters, and pumps expressed in inner 
ear epithelial and mesenchymal cells. 
Pendrin is an exchanger for anions such as of Cl− 
and HCO3− that contributes to fluid homeostasis 
[12-15]. Pendrin is expressed in epithelial cells in the 
inner ear including spindle cells of stria vascularis, 
outer sulcus and spiral prominence cells of the 
cochlea, transitional cells in the vestibular labyrinth, 
and mitochondria-rich cells of the endolymphatic sac 
(Figure 1A-E) [16, 17]. During development of the 
murine inner ear, pendrin expression is first observed 
at embryonic day (E) 11.5 in the endolymphatic sac, 
where expression increases dramatically between 
E13.5 and E14.5 [12, 18]. Pendrin expression in the 
cochlea, saccule, and utricle begins at E14.5 and in the 
crista ampullaris at E16.5 (Figure 1F) [12]. 
The pathogenesis of hearing loss caused by 
SLC26A4 mutations has been studied in mouse 
models, mainly in a knock-out Slc26a4∆/∆, a knock-in 
Slc26a4tm1Dontuh/tm1Dontuh, and an ENU-induced 
Slc26a4loop/loop mutant, and in a couple of transgenic 
models [19-23]. Mouse models congenitally lacking 
functional pendrin exhibited profound hearing loss 
and vestibular dysfunction together with enlargement 
of endolymphatic spaces [19, 20]. Studies in transgenic 
mouse models led to the hypothesis that temporally 
and spatially limited restoration of pendrin function is 
sufficient to prevent hearing loss in Slc26a4-deficient 
mice [21, 22]. Choi et al. demonstrated that the 
requirement of pendrin expression is temporally 
limited to the seven day period from E16.5 to 
postnatal day (P) 2 [21] and Li et al. reported that the 
requirement of pendrin expression is spatially limited 
to the endolymphatic sac [22]. 
 
 
Figure 1. Transcription of recombinant viral vectors in the embryonic inner ear. (A) Schematic diagram of the membranous inner ear. (B-E) Schematic diagrams of 
parts of the inner ear where natural pendrin expression occurs. (B) Schematic cross-section of the endolymphatic sac and duct. (C) Schematic cross-section of one turn of the 
cochlea.  Lig, spiral ligament; Lim, limbus; OC, organ of Corti; RM, Reissner's membrane; R, root cell; SP, spiral prominence; SV, stria vascularis. (D) Schematic cross-section of 
the utricle or saccule. (E) Schematic cross-section of an ampulla. (F) Onset of pendrin expression in different parts of the inner ear during development from embryonic (E) day 
9 to postnatal (P) day 16. (G) Schematic diagrams of viral vectors. The rAAV2/1-Slc26a4-tGFP vector expressed Slc26a4 and turbo GFP (tGFP) driven by the same CMV promoter. 
The rAAV2/1-tGFP vector, which was used as a control, expressed only tGFP under the control of the CMV promoter. CMV, cytomegalovirus; ITR, inverted terminal repeat from 
AAV2; Slc26a4, solute carrier family 26 member 4. GFP, green fluorescent protein. (H) mRNA expression in the inner ear. Transcripts of endogenous or vector-induced Slc26a4+ 
mRNA (478 bp), of Slc26a4Δ (894 bp) and Slc26a4tm1Dontuh (395 bp) mRNA as well as vector-induced tGFP (219 bp) mRNA and endogenous Gapdh (202 bp) mRNA were amplified 
by RT-PCR and separated by gel-electrophoresis. Reactions were performed with total RNA isolated from inner ears of Slc26a4+/+, Slc26a4Δ/Δ, rAAV2/1-Slc26a4-tGFP injected 
Slc26a4Δ/Δ, Slc26a4tm1Dontuh/tm1Dontuh, and rAAV2/1-Slc26a4-tGFP injected Slc26a4tm1Dontuh/tm1Dontuh mice. The ladder consisted of markers between 100 and 1000 bp in 100 bp intervals. 





We hypothesized that local gene delivery is 
suitable to restore hearing and balance in 
Slc26a4-deficient mice. We used a recombinant viral 
vector to deliver Slc26a4 to otocysts of 
Slc26a4-deficient Slc26a4∆/∆ and Slc26a4-deficient 
Slc26a4tm1Dontuh/tm1Dontuh mice. Gene-delivery resulted in 
spatially and temporally limited pendrin expression, 
prevented enlargement, failed to restore vestibular 
function, but succeeded to restore hearing. Restored 
hearing phenotypes included normal hearing as well 
as sudden, fluctuating, and progressive hearing loss. 
To our knowledge, local gene delivery has never 
before been used for Slc26a4 or to target the 
endolymphatic sac of the inner ear. Our study 
illustrates the feasibility of gene therapy for 
pendrin-related hearing loss, suggests differences in 
the pendrin requirement for the cochlea and the 
vestibular labyrinth, and suggest that sudden, 
fluctuating and progressive hearing loss can be the 
result of insufficient pendrin expression even when 
no enlargement of the membranous labyrinth is 
observed. 
Materials and Methods 
Animals 
Slc26a4∆/∆ and Slc26a4tm1Dontuh/tm1Dontuh mice were 
obtained from the National Institutes of Health (USA) 
and the University of Taiwan, respectively [19, 20] 
and maintained free of known and suspected murine 
pathogens in a pathogen-free animal facility. 
Slc26a4∆/∆ and Slc26a4+/+ mice were generated by 
mating Slc26a4∆/+ mice maintained in the 129S 
background. Slc26a4tm1Dontuh/tm1Dontuh and Slc26a4+/+ 
mice were generated by mating Slc26a4tm1Dontuh/+ mice 
maintained in the C57BL/6 background. All animal 
protocols were approved by the Institutional Animal 
Care and Use Committee of at the Kyungpook 
National University and Yonsei University College of 
Medicine.  
Local gene delivery via recombinant 
adeno-associated virus (rAAV)  
Recombinant adeno-associated virus (rAAV) 
used in the present study contained the inverted 
terminal repeat (ITR) of AAV serotype 2, the capsid of 
AAV serotype 1 (rAAV2/1) and a cytomegalovirus 
(CMV) promoter to drive expression. rAAV2/1 were 
packaged either with murine Slc26a4 cDNA (2,342 bp 
CDS excluding 3’ and 5’ UTR) fused with turbo green 
fluorescent protein (tGFP) gene 
(rAAV2/1-Slc26a4-tGFP) or with tGFP gene 
(rAAV2/1-tGFP) (Figure S1). Pre-packaged rAAVs 
were obtained from SignaGen Laboratories 
(Rockville, MD, USA). Titers of stocks, defined as 
vector genome copies per milliliter (VG/ml), were 
1.08x1013 VG/ml for rAAV2/1-Slc26a4 and 1.1x1013 
VG/ml for rAAV2/1-tGFP. Approximately 0.6-1 µl of 
rAAV2/1-Slc26a4-tGFP or rAAV2/1-tGFP (1.08x1010 
VG for rAAV2/1-Slc26a4 and 1.1x1010 VG for 
rAAV2/1-tGFP) was microinjected into the left 
otocyst of E12.5 embryos. Stocks were stored at -80°C 
and thawed immediately prior to use. 
Time-pregnant dams were generated by mating 
for 1 or 2 days. Pregnancy was assumed based on 
observation of a vaginal plug. The developmental age 
at the day a vaginal plug was observed was set to 
E0.5. Pregnant dams were anesthetized by a mixture 
of alfaxan (4 mg/100 g) and xylazine hydrochloride 
(0.13 mg/100 g) by intramuscular (i.m.) injection and 
were placed on a heating pad. All surgical procedures 
were conducted as described elsewhere [24]. 
Histology and immunocytochemistry 
Fixation 
Mice were deeply anesthetized with a mixture of 
alfaxan (4 mg/100 g) and xylazine hydrochloride (0.13 
mg/100 g) by i.m. injection. The postnatal mice were 
fixed by cardiac perfusion with 4% paraformaldehyde 
(PFA) in phosphate buffered saline (PBS), and then 
the inner ears were isolated from experimental mice. 
Extracted temporal bones, including the inner ear, 
from embryonic mice were fixed by submersion in 4% 
PFA in PBS without cardiac perfusion. 
Cryosections 
Fixed temporal bones from postnatal mice were 
decalcified for 24-48 hours (h) in 10% 
ethylenediaminetetraacetic acid (EDTA) in PBS. All 
tissues were dehydrated with 30% sucrose in PBS and 
a 1:1 30% sucrose:Optimal Cutting Temperature 
(OCT) compound mixture (Leica Microsystems, 
Bensheim, Germany) for 24 h each at 4°C. The 
temporal bones were then embedded in OCT 
compound. The embedded blocks were serially 
sectioned by cutting the tissues into 10-μm-thick slices 
using a microtome (Leica CM1850, Leica 
Microsystems, Bensheim, Germany). 
Paraffin sections  
The fixed inner ears were decalcified with 10% 
EDTA in PBS for 24 h at 4°C, dehydrated with a 
graded ethanol series, permeabilized with xylene, and 
embedded in paraffin at 65°C to initiate the 
embedding, and then cooled at room temperature 
(RT) to solidify the paraffin. The paraffin-embedded 
inner ears were then serially sectioned into 5-μm-thick 
slices using a microtome (Leica RM2235, Leica 
Microsystems, Bensheim, Germany). All tissue 
sections were mounted on Superfrost Plus microscope 





slides (Fisher Scientific, Pittsburgh, PA, USA). The 
slides with cryosections and paraffin sections were 
maintained at -80°C and RT, respectively, until use. 
Immunofluorescence and direct GFP fluorescence 
Immunofluorescence assays were conducted as 
described previously [24] with some modifications: 
primary antibodies were a rabbit polyclonal 
anti-pendrin antibody, that recognizes the amino 
acids CKDPLDLMEAEMNAEELDVQDEAMRRLAS 
(1:500; provided by Prof. Min Goo Lee at Yonsei 
University College of Medicine, Seoul, Korea), and a 
mouse anti-Kcnj10 antibody (1:500; Abnova, Taipei, 
Taiwan) diluted in the blocking solution, and the 
secondary antibody was an Alexa Fluor 
555-conjugated goat anti-rabbit IgG antibody (1:1000; 
Invitrogen, La Jolla, CA, USA) diluted in the blocking 
solution. The slides were mounted with an aqueous 
medium (Fluoromount, Sigma–Aldrich, St. Louis, 
MO, USA). GFP fluorescence was detected directly. 
Images were captured by conventional microcopy 
(Axioscope, Axio Imager.A2, Carl Zeiss, Inc., 
Oberkochen, Germany) or confocal laser microscopy 
(LSM700 with ZEN 2012 software, Carl Zeiss, Inc., 
Oberkochen, Germany). DAPI and pendrin 
expressing epithelial cell in the endolymphatic sac 
were counted using a computer algorithm (ImageJ, 
National Institutes of Health, Bethesda, MD, USA). 
Counts were verified by manual counting. The 
density of pendrin expressing epithelial cells in the 
endolymphatic sac was determined as ratio of 
pendrin- and DAPI-positive cells.  
Hematoxylin-eosin staining 
Before processing the hematoxylin-eosin 
staining, the slides of OCT compound-embedded 
inner ear sections were washed with PBS, whereas the 
slides of paraffin-embedded inner ear sections were 
incubated for 1 h at 65°C, deparaffinized with xylene, 
and rehydrated with a graded ethanol series. All 
slides of the inner ears were coverslipped with 
mounting media (Leica Microsystems, Bensheim, 
Germany) and visualized using a Zeiss Axio 
microscope (Axio Imager.A2, Carl Zeiss, Inc., 
Oberkochen, Germany). 
Reverse-transcription polymerase chain 
reaction (RT-PCR) 
The inner ears were divided by microdissection 
into three parts, cochlea, vestibule and endolymphatic 
sac and total RNA was isolated from each part 
according to the manufacturer’s instructions 
(RNeasy® Micro or Mini Kit, Qiagen, Hilden, 
Germany). cDNAs were synthesized from the isolated 
total RNA (High-Capacity cDNA Reverse 
Transcription Kit, Applied Biosystems, Foster City, 
CA, USA) and expression of Slc26a4 was analyzed by 
conventional and quantitative PCR (q-PCR) in 5 ng 
samples of cDNA.  
We designed one forward primer in exon 6 of the 
Slc26a4 and two reverse primers. The Slc26a4 
reverse-1 primer was located at the exon boundary 
between exons 7 and 8 and generated a 221 bp 
product with the Slc26a4+ cDNA and no product with 
Slc26a4∆ and Slc26a4tm1Dontuh cDNAs, both of which are 
lacking exon 8. The Slc26a4 reverse-2 primer was 
located at exon 10 and generated a 478 bp product 
(395 bp of flanking DNA and 83 bp from the wild-type 
exon 8) with Slc26a4+ cDNA, a 894 bp product (395 bp 
of flanking DNA and 499 bp of the NeoR cassette that 
replaced exon 8) with Slc26a4∆ cDNA, and a 395 bp 
product (without 83 bp from the wild-type exon 8) 
with Slc26a4tm1Dontuh cDNA. The presence of viral 
vector rAAV2/1-Slc26a4 was demonstrated by 
amplifying a 219 bp product in the tGFP gene. The 
glyceraldehyde 3-phosphate dehydrogenase (Gapdh) gene 
was amplified in all samples (202 bp) as a positive 
control. q-PCR was performed using SYBR green 
reagents (Applied Biosystems, Foster City, CA, USA) 
and a thermocycler (Step One RT-PCR, Applied 
Biosystems, Foster City, CA, USA). Relative Slc26a4+ 
mRNA expression was calculated by normalizing the 
level of the Slc26a4+ transcripts to the level of the 
Gapdh transcript in every sample and then to the 
normalized Slc26a4+ transcript level in Slc26a4+/+ mice 
at age E14.5 (∆∆Ct). ∆∆Ct values were used for 
statistical analysis. Relative fold changes were 
calculated (2-(∆∆Ct)) and graphed. Averages of three 
technical replicates of three biological replicates were 
analyzed. The following PCR primer sequences were 
used: Slc26a4 forward, 5’ ATC GTG CTC AAT GTT 
TCA ACC 3’; Slc26a4 reverse-1, 5’ GTA GCA ATT 
ATT GTC ACA ATC AC 3’; Slc26a4 reverse-2, 5’ ATC 
CAG AGA AGA CGT TGC TTA TCC 3’; tGFP 
forward, 5’ CTT CTA CCA CTT CGG CAC CTA C 3’; 
tGFP reverse, 5’ ATC TTG TCG GTG AAG ATC ACG 
3’; Gapdh forward, 5’ GGT GCT GAG TAT GTC GTG 
GA 3’; and Gapdh reverse, 5’ CTA AGC AGT TGG 
TGG TGC AG 3’. 
Paint fill 
The paint filling of the inner ears was performed 
using a method similar to that in a previous report 
[25]. Briefly, P2 mice were anesthetized with using 
hypothermia on ice and sacrificed by decapitation. 
Heads were bisected and fixed overnight in Bodian’s 
fixative (75% ethanol, 5% glacial acetic acid, 5% 
formalin, and 15% water). The bisected heads were 
then dehydrated in ethanol and cleared overnight in 
methyl salicylate. The inner ears were partially 
injected with white paint in methyl salicylate to 





visualize the cochlear duct, saccule, endolymphatic 
duct and sac. At least five inner ears were injected for 
each group presented. 
Auditory brainstem responses (ABR) 
Hearing thresholds were determined in a 
sound-proofed room based on ABR recordings (ABR 
workstation - System 3, Tucker Davis Technology, 
Alachua, FL, USA), as previously described [26]. Mice 
were anesthetized with a mixture of alfaxan (4 
mg/100 g) and xylazine hydrochloride (0.13 mg/100 
g) by i.m. injection and were placed on a heating pad. 
Subcutaneous needle electrodes were inserted into the 
vertex (channel), ipsilateral ear (reference), and 
contralateral ear (ground). Acoustic stimuli were 
applied monaurally through a speaker, and 
recordings were made in response to click and tone 
burst stimuli at frequencies of 8, 16, and 32 kHz. 
Stimuli were delivered at an amplitude of 90 dB 
sound pressure level (SPL) and amplitudes were 
reduced in 5 dB to determine acoustic thresholds. 
When no wave form was found, suggesting deaf, the 
threshold was set to the number 100 to allow 
numerical statistics. 
Endocochlear potential and endolymphatic pH 
Mice were anesthetized with 4% 
tribromoethanol (0.014 ml/g i.p.) and sacrificed by 
decapitation at the end of the procedure. The round 
window of the cochlea was exposed via a ventral 
approach. Endocochlear potential (EP) and 
endolymphatic pH were measured by advancing a 
double-barreled microelectrode through the round 
window membrane and the basilar membrane into 
scala media of the cochlea using previously described 
protocols [14]. After the microelectrode was 
positioned in the perilymphatic space, the surgical 
field was covered with liquid Sylgard 184 (Dow 
Corning Corporation, Midland, MI, USA) to limit 
dehydration and loss of tissue CO2. After advancing 
the electrode into endolymph and measurements of 
the transepithelial potentials and fluid pH values, the 
electrode was withdrawn and immediately calibrated 
in the surgical field [14]. Standard solutions for 
calibration were pH 6 (130 mM NaCl, 20 mM MES), 
pH 7 (130 mM NaCl, 20 mM HEPES), and pH 8 (130 
mM NaCl, 20 mM tricine). Data were recorded digital 
(Digidata 1440A and AxoScope 10, Molecular Devices, 
Sunnyvale, CA, USA) and analyzed using Origin 8 
software (The Origin Company, Northhampton, MA, 
USA). 
Double-barreled microelectrodes were fabricated 
from filament-containing glass tubing (World 
Precision Instruments 1B100F-4, Sarasota, FL, USA) 
using micropipette puller (Narishige PE-22, Tokyo, 
Japan). Microelectrodes were baked at 200°C for 2 h. 
After baking, ion barrels of the double-barreled 
microelectrodes were mounted on the holes in the lid 
of beaker, which heated to 210°C. Then, 20 µl 
dimethyldichlorsilane (Sigma-Aldrich, St Louis, MO, 
USA) was dripped into the beaker and the 
microelectrodes were silanized by exposing them to 
vaporized dimethyldichlorsilane for 30-35 seconds (s). 
After silanization, microelectrodes were baked at 
200°C for 3 h. The tips of microelectrodes were broken 
to outer diameter of ~5 µm. Reference barrel of 
microelectrode was filled with 1M KCl and the ion 
selective barrel was filled at the tip with liquid ion 
exchanger (Hydrogen ionophore I – cocktail A, 95291, 
Sigma-Aldrich, St Louis, MO, USA) and back-filled 
with buffer solution (500 mM KCl, 20 mM HEPES, pH 
7.34). Each barrel was connected to a dual channel 
differential electrometer (HiZ-223, Warner 
Instruments, Hamden, CT, USA) via Ag-AgCl wires. 
Scanning electron microscopy (SEM) 
Mice were anesthetized with a mixture of alfaxan 
(4 mg/100 g) and xylazine hydrochloride (0.13 
mg/100 g) by i.m. injection and sacrificed by 
decapitation. The inner ears were immediately 
harvested from the sacrificed mice and perfused 
cautiously through the oval window with a solution 
of 2% PFA dissolved in 0.1 M sodium cacodylate 
buffer (pH 7.4) containing 2.5% glutaraldehyde. The 
prepared specimens were immersed in the same 
fixative for 1 h at RT. The organ of Corti was prepared 
by the osmium tetroxide – thiocarbohydrazide 
(OTOTO) method, as described previously [24]. The 
specimens were examined under a cold-field emission 
SEM (SU8220, Hitachi, Tokyo, Japan) that was 
operated at 15 kV. 
Rotarod 
The ability of mice to balance on a revolving rod 
was quantified by measuring the latency to fall (47650 
Rota-Rod NG, Ugo Basile, Varese, Italy). On the day 
of testing, the cohort in their home cages was placed 
in the testing room at least 30 minutes before the 
actual test to allow them to acclimate to the 
environment. For each test, mice were placed in 
individual lanes on the Rotarod. The initial rotation 
speed was set to 5 revolutions per minute (rpm) and 
speed was accelerated to 40 rpm over 60 s. Mice were 
tested on 9 consecutive days in 4 trials per day spaced 
by 15-minute intertrial pauses. Daily medians were 
calculated for each mouse. Averages and standard 
deviations were obtained for each group of mice. The 
n is the number of mice.  
Statistical analyses 
Data were plotted directly, presented by 





averages ± SD or by box-plots indicating median, 25% 
and 75% of the data. Whiskers in box plots represent 
5% and 95% of the data. Data sets that failed the 
Shapiro-Wilk normality test were transformed 
according to xtransformed = log (x) when data sets did not 
contain negative values and when data sets contained 
negative values according to xtransformed = log (x + 1 - 
xmin), where xmin is the minimum value in the dataset. 
Significance of differences among groups represented 
by raw or transformed data sets that passed the 
Shapiro-Wilk normality test were determined by 
one-way or two-way ANOVA followed by 
all-pairwise multiple comparison procedures 
(Bonferroni t-test). Significance of differences among 
groups represented by data sets that did not pass the 
Shapiro-Wilk normality test was determined by 
Kruskal-Wallis one-way ANOVA on ranks followed 
by multiple comparisons versus a control group 
(Dunn's Method). Pearson correlation was used to 
evaluated interactions. Pearson correlations were 
interpreted based on ranges of the absolute R value: 
strong, 1.0 ≤ R ≤ 0.5; moderate: 0.5 < R ≤ 0.3; weak: 0.3 
< R ≤ 0.1. Significance of data in contingency tables 
was determined by Fisher’s exact test. Statistical 
analyses were assisted by software packages (SPSS 
Statistics 21.0, IBM, Chicago, IL, USA or Sigmastat 4.0, 
Systat Software, San Jose, CA, USA). p<0.05 was 
considered significant. 
Results 
Injection of rAAV2/1-Slc26a4-tGFP at E12.5 
targets epithelial cells in the developing 
endolymphatic sac 
Recombinant adenovirus rAAV2/1 vectors 
carrying Slc26a4 and tGFP cDNAs under the control 
of a CMV promoter (rAAV2/1-Slc26a4-tGFP) were 
used to transfect inner ears of Slc26a4-deficient mice 
(Figure 1G). Vectors were injected in utero into E12.5 
otocysts of two Slc26a4-deficient mice, knockout 
(Slc26a4∆/∆) and knock-in (Slc26a4tm1Dontuh/tm1Dontuh) 
mice. Expression of Slc26a4 and tGFP transcripts in 
the inner ear were examined by PCR using the Slc26a4 
forward and the Slc26a4 reverse-2 primer as well as 
forward and reverse tGFP primers (Figure 1H). The 
replacing form of Slc26a4 mRNA with the NeoR 
cassette instead of exon 8 and the skipping form of 
Slc26a4 mRNA lacking exon 8 were detected in the 
Slc26a4∆/∆ and Slc26a4tm1Dontuh/tm1Dontuh mice, 
respectively (Figure 1H, upper panel, lanes 3 and 5). 
When we delivered rAAV2/1-Slc26a4-tGFP, the 
mRNA expression of wild-type Slc26a4 mRNA was 
observed in the inner ear at E13.5, 24 hours after virus 
injection (Figure 1H, upper panel lane 4 and 6). We 
also determined that mRNA expression of the tGFP 
was only detectable in the inner ear of injected mice 
(Figure 1H, middle panel). Amplification of a 202 bp 
transcript representing the expression of Gapdh 
mRNA served as a control. The data demonstrate that 
local gene delivery induced onset of expression of 
Slc26a4 and tGFP mRNAs by one day after injection. 
Expression of pendrin and tGFP protein was 
examined by confocal immunocytochemistry and 
direct fluorescence, respectively. Pendrin-positive 
cells were detected in the endolymphatic sac of 
Slc26a4+/+ mice but not in Slc26a4∆/∆ or 
Slc26a4tm1Dontuh/tm1Dontuh mice (Figure 2). Injection of 
rAAV2/1-Slc26a4-tGFP induced pendrin and tGFP 
expression in the endolymphatic sac (Figure 2). 
Whether pendrin-positive cells were 
mitochondria-rich or ribosomal-rich cells remained 
undetermined. In contrast to the expression of 
exogenous pendrin protein in the endolymphatic sac, 
no pendrin expression was detected in the cochlea or 
in vestibular transitional cells of injected mice (Figure 
S2 and S3). Ectopic expression of exogenous pendrin, 
however, was detected in vestibular hair cells at P10 
(Figure S4). In addition, injection of rAAV2/1-tGFP 
showed poor tropism of rAAV2/1-tGFP to the 
cochlear and vestibular hair cells in both 
Slc26a4-deficient mice (Figure S5 and S6), which was 
consistent with tropism of rAAV2/1-Slc26a4-tGFP. 
Local gene delivery restores hearing 
Hearing was evaluated at 3-5 weeks of age based 
on ABR thresholds in response to click and sound 
stimuli. Slc26a4-deficient Slc26a4∆/∆ and 
Slc26a4tm1Dontuh/tm1Dontuh mice were profoundly deaf. 
ABR recordings appeared “flat” since characteristic 
waveforms were not observed, not even at the highest 
stimulus amplitude (90 dB). Injection of 
rAAV2/1-Slc26a4-tGFP restored ABR waveforms. 
Ranges of ABR thresholds obtained in injected mice 
overlapped with ranges in Slc26a4+/+ mice, however, 
variances of ABR thresholds were larger in injected 
mice (Figure 3A). Similar observations were made in 
response to tone bursts at 8, 16 and 32 kHz (Figure 
3B-D). Medians of ABR thresholds were 10-20 dB 
higher in injected compared to Slc26a4+/+ mice, which 
is consistent with a mild hearing impairment. 
To determine whether hearing restoration was 
induced by the injection or transfection procedure 
rather than the delivery of Slc26a4, we injected a 
control vector, rAAV2/1-tGFP, which lacks Slc26a4. 
Injection of rAAV2/1-tGFP failed to restore hearing in 
Slc26a4-deficient mice. Thresholds were 100 ± 0 dB 
SPL (n=3) in rAAV2/1-tGFP vector injected Slc26a4∆/∆ 
mice and 100 ± 0 dB SPL (n=3) in rAAV2/1-tGFP 
vector injected Slc26a4tm1Dontuh/tm1Dontuh mice. These 
results strengthen the conclusion that local gene 





delivery of Slc26a4 restores the acquisition of hearing 
in Slc26a4-deficient mice. 
Local gene delivery prevents enlargement of 
the membranous labyrinth and loss of hair 
cells 
Gross morphology of the cochlea was evaluated 
in histological sections and by the paint-fill method 
(Figure 4 and S7). Cross sectional areas of scala media 
of the cochlea were enlarged by a factor of 6.7 and 6.6 
in E16.5 Slc26a4∆/∆ and Slc26a4tm1Dontuh/tm1Dontuh mice 
compared to Slc26a4+/+ mice, respectively (Figure 4C, 
see Supplementary Excel File). Injection of 
rAAV2/1-Slc26a4-tGFP reduced this enlargement and 
cross sectional areas differed only by factor of 0.8 and 
1.5 from Slc26a4+/+ mice, respectively. Similar 
observations were made at E14.5 and P0 (Figure 4B 
and D). In addition, overt enlargements of the 
neonatal and adult endolymphatic sac and the adult 
vestibular labyrinth were observed in 
Slc26a4-deficient Slc26a4∆/∆ and Slc26a4tm1Dontuh/tm1Dontuh 
mice (Figure S7). Injection of rAAV2/1-Slc26a4-tGFP 
prevented enlargement not only of the neonatal but 
also the adult membranous labyrinth. 
The morphological integrity of the organ of Corti 
at the adult stage (5 weeks) was evaluated by SEM. 
Severe degeneration of outer hair cells was observed 
in Slc26a4-deficient Slc26a4∆/∆ and 
Slc26a4tm1Dontuh/tm1Dontuh mice in the basal turn of the 
cochlea (Figure 5). Injection of rAAV2/1-Slc26a4-tGFP 
led to the preservation of outer hair cells. Similar 
observations were made in the apical and middle turn 
of the cochlea (Figure 5). 
Local gene delivery induces Slc26a4 mRNA 
and transient pendrin protein expression in 
the endolymphatic sac 
To quantify the level of Slc26a4 mRNA and 
pendrin protein that was induced following delivery 
of the viral vector, we next performed quantitative 
analysis of the injected mice. Relative expression 
levels of Slc26a4+ mRNA were determined by qPCR 
using the Slc26a4-forward primer and Slc26a4 
reverse-1 primer, which amplified a transcript (221 
bp) from endogenous or vector-induced Slc26a4+ 
mRNA expression (Figure 6A-C, see Supplemental 
Excel File). The data demonstrate that local gene 
delivery induced Slc26a4+ mRNA expression in the 
endolymphatic sac, cochlea and vestibular labyrinth. 
At E14.5, densities of pendrin expressing cells in 
injected mice were similar or higher than in Slc26a4+/+ 
mice (Figure 6D and E). Densities declined in injected 
mice from E14.5 to P0 (Figure 6E) and no pendrin 
expressing cells were found at the adult stage (5 
weeks of age, data not shown).  
Local gene delivery partially rescued stria 
vascularis and the endocochlear potential but 
not the endolymphatic pH 
Stria vascularis and spiral ligament were 
evaluated in histologic sections and by 
immunocytochemistry of KCNJ10, the K+ channel that 
 
 
Figure 2. Pendrin and tGFP protein expression in the endolymphatic sac. Pendrin immunoreactivity (red) and direct fluorescence of tGFP (green) were evaluated in 
endolymphatic sacs of Slc26a4+/+, Slc26a4Δ/Δ, injected Slc26a4Δ/Δ, Slc26a4tm1Dontuh/tm1Dontuh, and injected Slc26a4tm1Dontuh/tm1Dontuh mice at E14.5 (a-e), E16.5 (f-j) and P0 (k-o). 
Endogenous pendrin expression was observed in mitochondria-rich cells Slc26a4+/+ mice (a, f, k). A similar pattern of rAAV2/1-Slc26a4-tGFP vector-induced pendrin and tGFP 
expression was observed in injected Slc26a4∆/∆ mice (c, h, m) and injected Slc26a4tm1Dontuh/tm1Dontuh mice (e, j, o). Nuclei were stained with DAPI (blue). White arrowheads point 
to representative pendrin-expressing cells. Representative images of 3 replicates each. Scale bars: 20 µm. 





generates the endocochlear potential. Atrophy of stria 
vascularis and spiral ligament was observed in 
Slc26a4-deficient Slc26a4∆/∆ and Slc26a4tm1Dontuh/tm1Dontuh 
mice, which resulted in a loss of KCNJ10 expression in 
stria vascularis (Figure 7Af-j), a reduced thickness of 
stria vascularis (Figure 7B), and a reduced area of 
spiral ligament (Figure 7C). Expression of KCNJ10 in 
spiral ganglion satellite cells served as a positive 
control (Figure 7Ak-o). Injection of rAAV2/1-Slc26a4 
largely restored the gross morphology of stria 
vascularis and spiral ligament in Slc26a4-deficient 
mice. No overt difference in the expression of KCNJ10 
was observed between injected Slc26a4∆/∆, injected 
Slc26a4tm1Dontuh/tm1Dontuh and Slc26a4+/+ mice. 
Thicknesses of stria vascularis and cross sectional 
areas of spiral ligament were not significantly 
different between injected Slc26a4tm1Dontuh/tm1Dontuh mice 
and Slc26a4+/+ mice, however, thicknesses of stria 
vascularis were larger and cross sectional areas of 
spiral ligament were smaller in injected Slc26a4∆/∆ 
mice compared to Slc26a4+/+ mice (Figure 7B and C).  
The endocochlear potential and endolymphatic 
pH were measured with double-barreled ion-selective 
microelectrodes in 5-6 week old mice (Figure 7D and 
E). The endocochlear potential was lost in Slc26a4∆/∆ 
and Slc26a4tm1Dontuh/tm1Dontuh mice and endolymph was 
more acidic. Injection of rAAV2/1-Slc26a4-tGFP 
partially restored the endocochlear potential. Injection 
increased endolymphatic potentials by approximately 
70 mV, however, potentials remained approximately 
20 mV lower than in Slc26a4+/+ mice. Endolymphatic 
pH values in injected Slc26a4-deficient mice were 
highly variable possibly indicating variability in the 
degree of restoration or instability in the pH 
homeostasis (Figure 7E). No significant difference was 
found between the endolymphatic pH of injected 
Slc26a4∆/∆ mice or injected Slc26a4tm1Dontuh/tm1Dontuh mice 
and Slc26a4+/+ mice, however, the power of this test 
was low (P=0.086), and thus the observation cannot be 
taken as evidence that injection of 




Figure 3. Local gene delivery restores hearing. Auditory brainstem response (ABR) thresholds in response to click sounds (A), tone burst at 8 kHz (B), 16 kHz (C) and 
32 kHz (D) tone bursts in Slc26a4+/+, Slc26a4Δ/Δ, injected Slc26a4Δ/Δ, Slc26a4tm1Dontuh/tm1Dontuh, and injected Slc26a4tm1Dontuh/tm1Dontuh mice at 3 to 5 weeks of age. Data are drawn as 
symbols and represented by box-plots (25%, 50%, and 75%) with whiskers (5% and 95%). Brackets mark comparisons among types of mice. Significance was evaluated by 
Kruskal-Wallis one-way ANOVA on ranks with Dunn’s method: n.s. no significant difference, * p<0.05, ** p<0.01, *** p<0.001 






Figure 4. Local gene delivery prevents enlargement of the cochlea. (A) Midmodiolar sections of the cochlea from Slc26a4+/+, Slc26a4Δ/Δ, injected Slc26a4Δ/Δ, 
Slc26a4tm1Dontuh/tm1Dontuh, and injected Slc26a4tm1Dontuh/tm1Dontuh mice were obtained at E16.5 (Aa-e) and stained with DAPI (blue) and obtained at 5 weeks of age (Af-j) and stained with 
hematoxylin-eosin. sm, scala media; sv, scala vestibuli, st, scala tympani, rm, Reissner’s membrane. Scale bars: 200 µm in (Aa-e) and 100 µm in (Af-j). (B-D) Quantification of 
cross sectional areas of scala media at E14.5 (B), E16.5 (C) and P0 (D). Numbers next to symbols represent the number of inner ears of the mice. Scala media was enlarged in 
Slc26a4-deficient Slc26a4∆/∆ and Slc26a4tm1Dontuh/tm1Dontuh mice. Injection of rAAV2/1-Slc26a4-tGFP reduced the enlargement. The ears of pendrin-deficient mice shown in this figure 
were the contralateral ears of injected pendrin-deficient mice. Significance was evaluated by two-way ANOVA with Bonferroni t-test: n.s. no significant difference, * p<0.05, *** 
p<0.001. 
 
Figure 5. Local gene delivery rescued outer hairs cells. The morphology of the organ of Corti at the apex (a-e), mid (f-j) and base (k-o) of the cochlea was examined by 
scanning electron microscopy in Slc26a4+/+ (a, f, k), Slc26a4Δ/Δ (b, g, l), injected Slc26a4Δ/Δ (c, h, m), Slc26a4tm1Dontuh/tm1Dontuh (d, i, n), and injected Slc26a4tm1Dontuh/tm1Dontuh mice (e, 
j, o) at 5 weeks of age. The ears of pendrin-deficient mice shown in this figure were the contralateral ears of injected pendrin-deficient mice. Representative images of 3 replicates 
each. Scale bar: 10 µm. 






Figure 6. Expression of the Slc26a4 mRNA, Pendrin and tGFP protein in the developing inner ear. (A-C) Relative Slc26a4+ expression in the endolymphatic sac, 
cochlea and vestibular labyrinth (mean ± SD). Numbers next to symbols represent the number of biological replicates. Transcripts of endogenous or vector-induced Slc26a4+ 
mRNA were quantified by qPCR. Reactions were performed on total RNA isolated from endolymphatic sacs (A), cochleae (B) and vestibular labyrinths (C) obtained from 
Slc26a4+/+, Slc26a4Δ/Δ, rAAV2/1-Slc26a4-tGFP injected Slc26a4Δ/Δ, Slc26a4tm1Dontuh/tm1Dontuh, and rAAV2/1-Slc26a4-tGFP injected Slc26a4tm1Dontuh/tm1Dontuh mice at ages E14.5, E16.5 
and P0. Relative fold changes (2-(∆∆Ct)) were obtained from relative Slc26a4+ mRNA expression levels (∆∆Ct) that were calculated by normalizing the level of Slc26a4+ transcripts 
to the level of Gapdh transcripts in every sample and then normalizing Slc26a4+ transcript levels to the average level in E14.5 endolymphatic sacs of Slc26a4+/+ mice. Slc26a4 
expression levels based on Ct values >30 were considered undetected and marked (grey shadow). Significance was evaluated by two-way ANOVA with Bonferroni t-test (A) and 
by one-way ANOVA on ranks with Tukey pairwise comparison (B-C). Brackets mark comparisons among types of mice: n.s., no significant difference, * p<0.05, ** p<0.01, *** 
p<0.001. Expression levels in the endolymphatic sac of rAAV2/1-Slc26a4-tGFP injected Slc26a4Δ/Δ and rAAV2/1-Slc26a4-tGFP injected Slc26a4tm1Dontuh/tm1Dontuh mice were 
compared to Slc26a4+/+ mice: #, no significant difference, $ p<0.05, $$$ p<0.001. Prior to statistical analysis, the data set shown in A was transformed to achieve normality. The 
data set is available in Supplemental Excel File. (D) Pendrin immunoreactivity (red) and direct fluorescence of tGFP (green) were evaluated in endolymphatic sacs of Slc26a4+/+, 
Slc26a4Δ/Δ, injected Slc26a4Δ/Δ, Slc26a4tm1Dontuh/tm1Dontuh, and injected Slc26a4tm1Dontuh/tm1Dontuh mice at E14.5 (Da-e), E16.5 (Df-j) and P0 (Dk-o). Endogenous pendrin expression was 
observed in mitochondria-rich cells Slc26a4+/+ mice (Da,f,k). A similar pattern of rAAV2/1-Slc26a4-tGFP vector-induced pendrin and tGFP expression was observed in injected 
Slc26a4∆/∆ mice (Dc,h,m) and injected Slc26a4tm1Dontuh/tm1Dontuh mice (De,j,o). The ears of pendrin-deficient mice shown in this figure were the contralateral ears of injected 
pendrin-deficient mice. Nuclei were stained with DAPI (blue). White arrowheads point to representative pendrin-expressing cells. Scale bars: 200 µm. (E) The density of 
pendrin-expressing cells, obtained as ratio of pendrin-immunoreactive and DAPI-stained epithelial cells, in endolymphatic sacs obtained from Slc26a4+/+, Slc26a4Δ/Δ, 
rAAV2/1-Slc26a4-tGFP injected Slc26a4Δ/Δ, Slc26a4tm1Dontuh/tm1Dontuh, and rAAV2/1-Slc26a4-tGFP injected Slc26a4tm1Dontuh/tm1Dontuh mice at ages E14.5, E16.5 and P0. Significance was 
evaluated by two-way ANOVA with Bonferroni t-test. Brackets mark comparisons among types of mice: *** p<0.001. Expression levels in the endolymphatic sac of 
rAAV2/1-Slc26a4-tGFP injected Slc26a4Δ/Δ and rAAV2/1-Slc26a4-tGFP injected Slc26a4tm1Dontuh/tm1Dontuh mice were compared to Slc26a4+/+ mice: #, no significant difference, $ 
p<0.05, $$$ p<0.001. The data set is available in Supplemental Excel File. 
 
The restored hearing phenotype is unstable 
ABR thresholds were obtained in weekly 
intervals to evaluate the hearing phenotype. 
Phenotypes of injected mice varied among 
individuals. Individuals with stable normal hearing as 
well as with stable hearing loss, sudden, progressive 
and fluctuating hearing loss were observed (Figure 
8A). Between 3 and 11 weeks of age, ABR thresholds 
in response to click sound stimuli were moderately 
correlated with age and rose at a rate of 2.9 dB/week 
in injected Slc26a4∆/∆ mice and at a rate of 4.9 dB/week 
in injected Slc26a4tm1Dontuh/tm1Dontuh mice. In contrast, 
ABR thresholds were only weekly correlated with age 
in Slc26a4+/+ mice (Figure 8B). Similar observations 
were made in response to tone burst stimuli (Figure 
S8A). Data were grouped by age to determine 
significance. Medians of hearing thresholds in 
response to click stimuli in injected mice at 16-21 
weeks of age were significantly higher than at 3-5 
weeks, whereas thresholds in Slc26a4+/+ mice were not 
significantly different (Figure 8C). No significant 





differences were found between injected Slc26a4∆/∆ 
and injected Slc26a4tm1Dontuh/tm1Dontuh mice. Similar 
observations were made in response to tone burst 
stimuli (Figure S8B). These data demonstrate 
progressive hearing loss in injected Slc26a4∆/∆ and 
injected Slc26a4tm1Dontuh/tm1Dontuh mice. 
Variances of ABR thresholds were larger in 
injected mice than in Slc26a4+/+ mice, which suggests 
that hearing is fluctuating. To detect hearing 
fluctuations, differences between successive weekly 
threshold measurements were computed (Figure S9). 
Differences larger than ±15 dB were considered 
fluctuations consisting of either a loss or a gain of 
hearing. Contingency tables of counts of animals that 
do or do not experienced fluctuations were evaluated 
using Fisher’s exact test. The fraction of mice that 
experienced fluctuations was larger in injected mice 
than in Slc26a4+/+ mice (Figure 8D). No significant 
differences were found between injected Slc26a4∆/∆ 
and injected Slc26a4tm1Dontuh/tm1Dontuh mice. The average 
frequency of fluctuations was 1 per 5 weeks in 
injected Slc26a4∆/∆ and injected Slc26a4tm1Dontuh/tm1Dontuh 
mice and 1 per 19 weeks in Slc26a4+/+ mice. Moreover, 
the fraction of mice that experienced losses >15 dB 
was greater in injected mice than in Slc26a4+/+ mice 
with no significant difference between the two 
injected mice (Figure 8E). Injected Slc26a4∆/∆ mice, 
however, experienced more gains >15 dB than 
injected Slc26a4tm1Dontuh/tm1Dontuh mice, although, this 
observation was supported only by measurements in 
 
Figure 7. Local gene delivery partially rescued stria vascularis and the endocochlear potential but not the endolymphatic pH. (A) Sections of the lateral wall 
and spiral ganglion region of the cochlea were obtained from inner ears of Slc26a4+/+, Slc26a4Δ/Δ, injected Slc26a4Δ/Δ, Slc26a4tm1Dontuh/tm1Dontuh, and injected Slc26a4tm1Dontuh/tm1Dontuh 
mice at 5 weeks of age. (Aa-e) Gross morphology was evaluated in sections of the lateral wall stained with hematoxylin-eosin. (Af-j) KCNJ10 immunoreactivity (red) was 
evaluated in sections of the lateral wall stained with DAPI (blue). (Ak-o) Sections of the spiral ganglion region stained with DAPI (blue) served as a positive control for KCNJ10 
immunoreactivity (red). SV, stria vascularis; sl, spiral ligament. Scale bars: 100 µm (Aa-e) and 50 µm (Af-o). The ears of pendrin-deficient mice shown in this figure were the 
contralateral ears of injected pendrin-deficient mice. (B-C) Thickness the stria vascularis and area of spiral ligament were measured in sections of the lateral wall. Data are drawn 
as symbols and represented by box-plots (25%, 50%, and 75%). Brackets mark comparisons among types of mice. Significance was evaluated by one-way ANOVA with Bonferroni 
t-test: n.s. no significant difference, * p<0.05, ** p<0.01, *** p<0.001. (D-E) Endocochlear potential and endolymphatic pH were measured in the inner ears of Slc26a4+/+, 
Slc26a4Δ/Δ, injected Slc26a4Δ/Δ, Slc26a4tm1Dontuh/tm1Dontuh, and injected Slc26a4tm1Dontuh/tm1Dontuh mice at 5 weeks of age. Data are drawn as symbols and represented by box-plots (25%, 
50%, and 75%) with whiskers (5% and 95%). Brackets mark comparisons among types of mice. Significance was evaluated by two-way ANOVA with Bonferroni t-test: n.s. no 
significant difference, * p<0.05. 
 





response to 8 and 32 kHz tone burst stimuli (Figure 
8F). The average frequency of hearing gains was 1 per 
16 weeks in injected Slc26a4∆/∆ and 1 per 32 weeks in 
injected Slc26a4tm1Dontuh/tm1Dontuh mice. Taken together, 
the data demonstrate considerable variability in the 
individual hearing phenotype of injected mice and 
overall a fluctuating and progressive hearing loss 
phenotype. The lower rate of hearing loss progression 
and higher frequency of hearing gains in Slc26a4∆/∆ 
mice compared to Slc26a4tm1Dontuh/tm1Dontuh mice may be 
an effect of the genetic background. The background 
strain of the Slc26a4∆/∆ mice, 129S6, is less prone to 
age- and noise-induced hearing loss than the C57BL/6 
strain, which provides the background of the 
Slc26a4tm1Dontuh/tm1Dontuh mice [27]. 
Loss of outer hair cells in mice with profound 
hearing loss 
Injected Slc26a4-deficient mice with profound 
hearing loss were evaluated by histology and by 
immunocytochemistry. No enlargement of scala 
media was observed in a deaf 26 week old injected 
Slc26a4∆/∆ mouse, and in two deaf 10 week old and an 
11 week old injected Slc26a4tm1Dontuh/tm1Dontuh mice 
(Figure S10A). Most notably, the loss of outer hair 
cells was observed (Figure S10B). No overt 
degeneration of stria vascularis or loss of KCNJ10 
expression were observed (Figure S10C). These 
observations suggest that profound deafness in 
injected Slc26a4-deficient mice was permanent. 
Local gene delivery fails to restore vestibular 
function 
The gross morphology of vestibular tissues was 
evaluated histologically and by SEM. Otoconia were 
replaced with mega-otoconia in Slc26a4∆/∆ and 
Slc26a4tm1Dontuh/tm1Dontuh mice (Figure 9A). 
Mega-otoconia were also observed in injected mice 
(Figure 9A and D). No overt differences between 
Slc26a4+/+ mice, injected and uninjected Slc26a4∆/∆ and 
Slc26a4tm1Dontuh/tm1Dontuh mice were observed in the 
structure of the otoconia membrane and in the 
appearance of vestibular hair cells (Figure 9B and C). 
Further, no overt differences were observed in the 
histology of the saccule, utricle, and crista ampullaris 
(Figure S11). Vestibular function was evaluated by the 
rotarod test, which measures the ability of an animal 
to maintain balance on a rotating rod. After a 4 to 5 
 
 
Figure 8. Restored hearing phenotype is unstable. (A) ABR thresholds in response to click sounds were obtained in weekly intervals. Examples from five injected 
Slc26a4∆/∆ mice that have normal stable hearing (black), stable hearing loss (blue), progressive hearing loss (green), sudden hearing loss (red) and fluctuating hearing loss (cyan). (B) 
Linear regressions of ABR thresholds in response to click stimuli were obtained in Slc26a4+/+ mice, injected Slc26a4∆/∆ and injected Slc26a4tm1Dontuh/tm1Dontuh mice between 3 and 
11 weeks of age. Slopes and Pearson’s R value were -0.6 dB/week and R=0.259, 2.9 dB/week and R=0.323, and 4.9 dB/week and 0.391, respectively. (C) ABR thresholds in 
response to click stimuli were grouped into three age ranges, 3-5 weeks (Slc26a4+/+ n=20, injected Slc26a4∆/∆ n=18, injected Slc26a4tm1Dontuh/tm1Dontuh n=16), 9-11 weeks (Slc26a4+/+ 
n=17, injected Slc26a4∆/∆ n=17, injected Slc26a4tm1Dontuh/tm1Dontuh n=10), and 16-21 weeks (Slc26a4+/+ n=10, injected Slc26a4∆/∆ n=4, injected Slc26a4tm1Dontuh/tm1Dontuh n=3) to evaluate 
the stability of hearing in Slc26a4+/+, injected Slc26a4∆/∆ mice and injected Slc26a4tm1Dontuh/tm1Dontuh mice. Data are represented by box-plots (25%, 50%, and 75%) with whiskers (5% 
and 95%). Outliers were drawn as symbols (diamonds). Differences toward the 3-5 week group were evaluated either by one-way ANOVA with Bonferroni t-test or by 
Kruskal-Wallis one-way ANOVA on ranks and Dunn’s method, n.s. no significant difference, * p<0.05, ** p<0.01, *** p<0.001. (D-F) Fraction of mice that experienced gains or 
losses (D), losses (E), or gains >15 dB (F) were obtained and differences between injected Slc26a4∆/∆ or injected Slc26a4tm1Dontuh/tm1Dontuh mice and Slc26a4+/+ mice were evaluated 
by Fisher’s exact test, * p<0.05, ** p<0.01, *** p<0.001. Brackets indicate significant differences between injected Slc26a4∆/∆ and injected Slc26a4tm1Dontuh/tm1Dontuh mice, ** p<0.01. 





days of training, 5-week-old Slc26a4+/+ mice were able 
to balance on the accelerating rod. Neither Slc26a4∆/∆ 
and Slc26a4tm1Dontuh/tm1Dontuh mice nor injected Slc26a4∆/∆ 
or injected Slc26a4tm1Dontuh/tm1Dontuh mice were able to 
balance on the rod (Figure 9E). These observations 
demonstrate that local gene delivery failed to restore 
otoconia and vestibular function in Slc26a4-deficient 
mice. 
Discussion 
The most salient findings of this study are that 
local AAV-mediated delivery of Slc26a4 causes 
transient pendrin expression in the endolymphatic 
sac, which prevents enlargement of the membranous 
labyrinth and that Slc26a4 delivery restores the 
acquisition of hearing but fails to restore a stable 
hearing phenotype and fails to restore otoconia 
formation and the acquisition of vestibular function.  
Local gene delivery induces transient pendrin 
expression in the endolymphatic sac 
Pendrin expression in Slc26a4+/+ mice begins at 
E11.5 in the endolymphatic sac, at E14.5 in outer 
sulcus epithelial cells in the cochlea and in transitional 
cells of the utricle and saccule, and at E16.5 in 
transitional cells of vestibular ampullae. At all of these 
sites, pendrin expression is maintained in Slc26a4+/+ 
mice throughout adulthood [12, 16]. Injection of 
rAAV2/1-Slc26a4-tGFP into E12.5 otocysts of 
 
 
Figure 9. Local gene delivery fails to restore otoconia and to rescue vestibular function. (A-C) The morphology of the otoconia in the utricle (A), the otoconia 
membrane (B) and the vestibular hair cells (C) were examined by scanning electron microscopy in the Slc26a4+/+, Slc26a4Δ/Δ, injected Slc26a4Δ/Δ, Slc26a4tm1Dontuh/tm1Dontuh, and 
injected Slc26a4tm1Dontuh/tm1Dontuh mice at 5 weeks of age. The ears of pendrin-deficient mice shown in this figure were the contralateral ears of injected pendrin-deficient mice. 
Representative images of 3 replicates each. Scale bars: 100 µm in (A), 5 µm in (B) and (C). (D) Quantification of otoconia length in the inner ears of the Slc26a4+/+, Slc26a4Δ/Δ, 
injected Slc26a4Δ/Δ, Slc26a4tm1Dontuh/tm1Dontuh, and injected Slc26a4tm1Dontuh/tm1Dontuh mice at 5 weeks of age. Data are drawn as symbols and represented by box-plots (25%, 50%, and 
75%) with whiskers (5% and 95%). Brackets mark comparisons among types of mice. Significance was evaluated by one-way ANOVA: n.s. no significant difference. (E) Rotarod 
tests, which evaluated whether a mouse can balance up to 400s on an accelerating revolving rod, were performed in Slc26a4+/+, Slc26a4Δ/Δ, injected Slc26a4Δ/Δ, 
Slc26a4tm1Dontuh/tm1Dontuh, and injected Slc26a4tm1Dontuh/tm1Dontuh mice at 5 weeks of age. 





Slc26a4-deficient mice induced Slc26a4+ mRNA 
expression and transient pendrin protein expression 
in the endolymphatic sac (Figure 6). The observation 
that injection induced no protein expression in the 
cochlea and no protein expression in vestibular 
transitional cells (Figure S2 and S3) is consistent with 
the tropism of the vector. A similar expression pattern 
was observed after injection of the rAAV2/1-GFP into 
E12.5 otocysts (Figure S5 and S6).  
Hearing and vestibular function differ in their 
requirements of pendrin expression  
Studies in different mouse models suggested 
that a temporally and spatially limited expression of 
pendrin is sufficient to restore normal hearing and 
balance in Slc26a4-deficient mice. Li et al 
demonstrated in transgenic Atp6v1b1-SLC26A4; 
Slc26a4∆/∆ mice that pendrin expression spatially 
limited to the endolymphatic sac is sufficient to 
restore normal hearing and vestibular function [22]. In 
contrast, Choi et al. had developed double-transgenic 
Slc26a4∆/∆ mice and proposed that the temporally 
limited expression of pendrin from E16.5 to P2 is 
sufficient for normal hearing [21]. Two sets of 
experiments consisting of a delayed onset of pendrin 
expression and a premature termination of pendrin 
expression bracketed a seven-day period between 
E16.5 to P2 that appeared to be critical for the 
development of normal hearing. Whether this 
seven-day period was sufficient to restore vestibular 
function remained undetermined [21]. The present 
study is the first to implement temporally and 
spatially limited expression simultaneously. Our 
protocol for gene delivery induced pendrin 
expression nearly exclusively in the endolymphatic 
sac. Expression did not fully cover the critical period 
between E16.5 to P2. Transient pendrin expression 
prevented enlargement of the membranous labyrinth 
and restored hearing but failed to restore otoconia 
formation and vestibular function (Figure 3, 4, and 9). 
Mega-otoconia may be the result of a lower 
endolymphatic pH and elevated endolymphatic Ca2+ 
concentrations [13]. The data demonstrate that 
development of hearing and vestibular function 
differs in the requirement for pendrin expression. 
Normal development of vestibular function appears 
to require an earlier onset, a higher level or a longer 
period of pendrin expression in the endolymphatic 
sac. 
Pendrin expression in the endolymphatic sac 
promotes the acquisition of a stable hearing 
phenotype 
Transient pendrin expression in injected 
Slc26a4∆/∆ and injected Slc26a4tm1Dontuh/tm1Dontuh mice 
prevented enlargement of the membranous labyrinth 
and restored hearing with average thresholds at 3-5 
weeks of age that were approximately 10-20 dB above 
thresholds in Slc26a4+/+ mice consistent with a mild 
hearing loss (Figure 3 and 4). Similar observations had 
been made in double-transgenic Slc26a4∆/∆ mice in 
which pendrin expression was discontinued at E17.5 
(DE17.5-Slc26a4∆/∆ mice), which is six days before the 
end of the critical period [28]. Limited pendrin 
expression in injected Slc26a4∆/∆ and injected 
Slc26a4tm1Dontuh/tm1Dontuh mice and in DE17.5-Slc26a4∆/∆ 
mice had similar consequences including a similar 
degree hearing loss, similar effects on the 
endocochlear potential, and the stability of hearing 
thresholds. In both models, the endolymphatic 
potential was reduced and measured 60 or 70 mV 
rather than 100 mV as observed in Slc26a4+/+ mice 
(Figure 7D). In DE17.5-Slc26a4∆/∆ mice the pH in 
cochlear endolymph was lower than in Slc26a4+/+ 
mice, and in both models variances of ABR thresholds 
were higher than in Slc26a4+/+ due to hearing 
fluctuations (Figure 3) [28]. Interestingly, a longer 
period of pendrin expression in the endolymphatic 
sac may be more important for the acquisition of a 
stable hearing phenotype than local expression of 
pendrin in the cochlea since hearing thresholds were 
normal and hearing was stable in 
Atp6v1b1-SLC26A4;Slc26a4∆/∆ mice, which lack 
pendrin expression in the cochlea but sustain pendrin 
expression in the endolymphatic sac [22].  
Pendrin expression in spindle-shaped cells 
stabilizes hearing 
The overall progression of hearing loss was 
notably faster in injected Slc26a4∆/∆ mice (2.9 
dB/week) and injected Slc26a4tm1Dontuh/tm1Dontuh mice 
(4.9 dB/week, Figure 8B) than in DE17.5-Slc26a4∆/∆ 
mice (0.4 dB/week) [28]. A key difference between 
these models is that injected Slc26a4∆/∆ mice and 
injected Slc26a4tm1Dontuh/tm1Dontuh mice lacked pendrin 
expression in spindle-shaped cells in the lateral wall 
of the cochlea (Figure S2) whereas DE17.5-Slc26a4∆/∆ 
mice expressed pendrin in spindle-shaped cells at a 
level of 10% of that observed in Slc26a4+/+ mice [29]. 
The concept that pendrin expression in 
spindle-shaped cells affects the frequency of 
fluctuations and the progression of hearing loss is 
supported by the finding that hearing thresholds in 
DE17.5-Slc26a4∆/∆ mice were lower and fluctuations 
diminished, when pendrin expression in 
spindle-shaped cells was elevated to 30% of that 
observed in Slc26a4+/+ mice [29]. Pendrin expression in 
spindle-shaped cells may contribute to the 
homeostasis of stria vascularis and this contribution 
may be more important for hearing in mice with a 





lower endolymphatic pH such as DE17.5-Slc26a4∆/∆ 
mice than in mice with a normal endolymphatic pH 
such as Atp6v1b1-SLC26A4;Slc26a4∆/∆ mice [22]. It is 
conceivable that rates of pendrin-mediated HCO3- 
secretion and Cl- absorption across the apical 
membrane of spindle-shaped cells are elevated at 
lower endolymphatic pH values, when the 
endolymphatic HCO3- concentration is lower and the 
HCO3- gradient steeper.  
Feasibility of gene therapy 
Our protocol of AAV2/1-Slc26a4-tGFP injection 
induced a transient pendrin protein expression nearly 
exclusively in the endolymphatic sac. This limited 
pendrin expression was sufficient to restore the 
acquisition of hearing but failed to restore a stable 
hearing phenotype and the acquisition of vestibular 
function. Earlier onset, longer periods or higher levels 
of pendrin expression in the endolymphatic sac may 
be necessary to fully restore cochlear and vestibular 
function. Our study suggests that gene therapy for 
hearing loss caused by SLC26A4 mutations in human 
patients is feasible, however, ethical concerns should 
prevent a direct translation, since local gene delivery 
amounts to an invasive procedure for a non-lethal 
disease. It will be necessary to develop non-invasive 
methods that induce sufficient pendrin function to 
ensure the development of robust cochlear and 
vestibular phenotypes.  
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